

17 July 2026

To
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Symbol: COHANCE

Dear Sir/Madam,

Sub: Clarification to the email received from NSE dated 10 July 2026

This is with reference to your email dated 10 July 2026 seeking clarification for Financial results with respect to Outcome of Board Meeting-Financial Results submitted to the Exchange dated 12-Nov-2025.

We wish to inform you that we have given the clarification regarding filing of Non-Machine Readable Form of Financial Results in our earlier communication dated 2 July 2026. Further we have submitted the revised Financial results XBRL on 17 July 2026.

Please take the above on record and close the matter.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(formerly, Suven Pharmaceuticals Limited)

Sisir K. Mishra
Company Secretary and Compliance Officer

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana.
Tel: +91 40 2354 9414 / 3311

Regd. Office: 215 Atrium, C-Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Andheri East, Mumbai, Maharashtra - 400093.
Tel: 022 6513999

CIN: L24299MH2018PLC422236 | Website: www.cohance.com | Company Email: reachus@cohance.com

